News Details - novonordisk.com
Sep 20, 2024 · Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 …
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
Sep 20, 2024 · Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link]. The trial investigated the efficacy and safety of a once-daily 10 mg,...
Monlunabant phase 2a trial in obesity successfully completed
Sep 20, 2024 · Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 …
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse...
Novo Nordisk shares phase 2a trial data for obesity treatment
Sep 20, 2024 · Novo Nordisk has completed its phase 2a clinical trial of monlunabant, an oral cannabinoid receptor 1 (CB1) inverse agonist, for obesity treatment. The study included 243 participants with obesity and metabolic syndrome, testing daily doses of …
Novo Nordisk Delivers Updates on Development of Semaglutide, …
Mar 7, 2024 · Monlunabant: Formerly INV-202, monlunabant is an oral small molecule CB1R inverse agonist. At their Capital Markets Day, Novo Nordisk presented data from a phase 1 trial indicating use was safe and well-tolerated, with efficacy results pointing to a statistically significant mean weight loss of 3.5 kg (3.3%) compared to 0.6 kg (0.5%) with ...
Novo Nordisk shares drop nearly 5% on disappointing obesity pill …
Sep 20, 2024 · Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Shares Fall on Safety Data for New Weight-Loss Drug - Bloomberg.com
Sep 20, 2024 · Monlunabant is an experimental compound that targets type 1 cannabinoid receptors, or CB1 receptors. The drug uses a similar approach to rimonabant, an obesity drug that European regulators...
Novo Nordisk’s obesity newcomer monlunabant heads into …
Sep 20, 2024 · Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity. The trial showed significant weight loss with a 10 mg dose, achieving a 7.1 kg reduction versus 0.7 kg for placebo.
Questions over Novo Nordisk $1bn weight loss drug after Phase …
Sep 23, 2024 · Questions remain over the efficacy-to-safety ratio of Novo Nordisk’s acquired weight loss drug monlunabant after a Phase IIa trial. The pharma giant announced results from the study (NCT05891834) which investigated monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist acquired in the $1bn Inversago Pharmaceuticals ...